[Monoclonal antibody therapy: a literature review].
Monoclonal antibodies (MA) are an important group of drugs used in oncology. The objective of this study was to identify MAs used in oncology, and to describe their pharmacological characteristics. This literature review was based on database, index, and library collections. Eight MA were identified, out of which, 37.4% are immunoconjugated, 62.5% are recommended for hematological neoplasms, 75.0% are diluted in saline solution and should not be mixed with other drugs, 100.0% cause digestive side effects, and 87.5% affect the hematopoietic system. In order to guarantee MA's therapeutic efficacy and safety, professionals must fully understand their pharmacological characteristics.
Del Debbio
Carolina Beltrame
CB
Escola de Enfermagem, Universidade de São Paulo.
Tonon
Lenita Maria
LM
Secoli
Silvia Regina
SR
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000276:immunology; D006402:Hematologic Diseases / Q000139:chemically induced; D019337:Hematologic Neoplasms / Q000276:immunology / Q000628:therapy; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007167:Immunotherapy; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D018796:Immunoconjugates; D009363:Neoplasm Proteins